Moffitt Cancer Center Appoints Ana Stancic CFO of M2Gen

June 23, 2010

TAMPA, Fla. – Moffitt Cancer Center announces the appointment ofAna Stancic as senior vice president and chief financial officer of M2Gen, a wholly owned for-profit subsidiary of Moffitt. Stancic will report to James D. Utterback, CEO of M2Gen. Stancic, as a key member of the M2Gen executive management team, will be responsible for providing the direction, leadership and management for all financial operations, control, internal audits and facility administration.

“We are excited about Ana joining our executive team,” Utterback said. “Her education and years of relevant experience will undoubtedly be put to good use as we accelerate M2Gen’s business planning and fundraising efforts across multiple business lines. Ana has great networks across the venture and health care industries that will be critical as we expand our client base in biopharmaceuticals.”

Stancic has more than 20 years of extensive and diversified finance, accounting and operational experience in the health care industry. Most recently, she served as chief financial officer of Aureon Laboratories, Inc., a private oncology diagnostic company. From 2007 to 2008, she was executive vice president and chief financial officer at Omrix Biopharmaceuticals, Inc., which was acquired by Johnson & Johnson. From 2004 to 2007, Stancic was at ImClone Systems, Inc., which was acquired by Eli Lilly, Inc. At ImClone, she served in various financial roles, including senior vice president, finance. Prior to joining ImClone, she was vice president and controller at Savient Pharmaceuticals, Inc.

Stancic began her career at PricewaterhouseCoopers in the Assurance practice where she had responsibility for international and national companies in the pharmaceutical and services industries. Stancic is a Certified Public Accountant and holds an M.B.A. from Columbia University Graduate School of Business. She currently serves as a member of the Board of Directors of Champions Biotechnology, Inc.

About M2Gen

M2Gen ™ is Moffitt Cancer Center’s wholly-owned, for-profit subsidiary focused on advancing personalized medicine by using high quality tissue, clinical data and molecular technology to advance targeted cancer treatments. M2Gen, along with Moffitt and 18 hospitals in a Consortium Network, has created the world’s largest cancer-focused biorepository linked to clinical and molecular data. Since 2006, M2Gen has partnered with Merck & Co., Inc., to fulfill its vision for transforming cancer treatment and improving patient outcomes.

About Moffitt Cancer Center

Located in Tampa, Florida, Moffitt Cancer Center  is an NCI Comprehensive Cancer Center - a designation that recognizes Moffitt’s excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 14 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.